LncRNA ABHD11-AS1 promotes tumor progression in papillary thyroid carcinoma by regulating EPS15L1/EGFR signaling pathway

Lu, Hongsheng; Zhu, Chumeng; Chen, Y; Ruan, Yiwen; Fan, Lilong; Chen, Q; Wei, Qing

doi:10.1007/s12094-021-02753-z

Cited by 5 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the lncRNAs were found to play critical roles in the initiation and progression of cancers, including thyroid cancer [ 46 , 47 ]. Several studies have reported that ABHD11-AS1 lncRNA is vital for PTC progression, and could be a potential therapeutic target [ 19 , 20 , 21 , 22 ]. In these studies, ABHD11-AS1 is highly expressed in PTC patient samples and cell lines (BCPAP, BHP2-7, BHP5-16, BHT-101, GLAG-66, IHH-4, K-1, KTC-1, and TPC-1), compared to normal tissues and the control cell line (Nthy-ori 3-1) respectively.…”

Section: Oncogenic Role Of Abhd11-as1 Lncrna In Human Cancersmentioning

confidence: 99%

“…In these studies, ABHD11-AS1 is highly expressed in PTC patient samples and cell lines (BCPAP, BHP2-7, BHP5-16, BHT-101, GLAG-66, IHH-4, K-1, KTC-1, and TPC-1), compared to normal tissues and the control cell line (Nthy-ori 3-1) respectively. The high levels of ABHD11-AS1 significantly correlated with PTC clinicopathological features, such as extrathyroidal extension, lymph node metastasis, tumor infiltration, tumor size, and advanced TNM (Tumor, Node, Metastasis) stage [ 19 , 20 , 22 ]. Kaplan–Meier analysis revealed the predictive value of ABHD11-AS1 in PTC, as the patients with higher ABHD11-AS1 had poorer overall survival [ 19 ].…”

Section: Oncogenic Role Of Abhd11-as1 Lncrna In Human Cancersmentioning

confidence: 99%

“…Analysis of TCGA datasets revealed that EGFR signaling pathway genes were highly expressed and enriched in PTC. Lu H. et al showed that knockdown of ABHD11-AS1 resulted in downregulation of Epidermal Growth Factor Receptor Pathway Substrate 15 Like 1 ( EPS15L1 ) [ 22 ]. A positive correlation between ABHD11-AS1 levels and the EGFR signaling pathway was observed in PTC cell lines.…”

Section: Molecular Mechanisms Of Abhd11-as1 Lncrna Dysregulation In H...mentioning

confidence: 99%

See 2 more Smart Citations

ABHD11-AS1: An Emerging Long Non-Coding RNA (lncRNA) with Clinical Significance in Human Malignancies

Golla

Sesham

Dallavalasa

et al. 2022

ncRNA

View full text Add to dashboard Cite

The aberrant expression of lncRNAs has been linked to the development and progression of different cancers. One such lncRNA is ABHD11 antisense RNA 1 (ABHD11-AS1), which has recently gained attention for its significant role in human malignancies. ABHD11-AS1 is highly expressed in gastric, lung, breast, colorectal, thyroid, pancreas, ovary, endometrium, cervix, and bladder cancers. Several reports highlighted the clinical significance of ABHD11-AS1 in prognosis, diagnosis, prediction of cancer progression stage, and treatment response. Significantly, the levels of ABHD11-AS1 in gastric juice had been exhibited as a clinical biomarker for the assessment of gastric cancer, while its serum levels have prognostic potential in thyroid cancers. The ABHD11-AS1 has been reported to exert oncogenic effects by sponging different microRNAs (miRNAs), altering signaling pathways such as PI3K/Akt, epigenetic mechanisms, and N6-methyladenosine (m6A) RNA modification. In contrast, the mouse homolog of AHD11-AS1 (Abhd11os) overexpression had exhibited neuroprotective effects against mutant huntingtin-induced toxicity. Considering the emerging research reports, the authors attempted in this first review on ABHD11-AS1 to summarize and highlight its oncogenic potential and clinical significance in different human cancers. Lastly, we underlined the necessity for future mechanistic studies to unravel the role of ABHD11-AS1 in tumor development, prognosis, progression, and targeted therapeutic approaches.

show abstract

Section: Oncogenic Role Of Abhd11-as1 Lncrna In Human Cancersmentioning

confidence: 99%

Section: Oncogenic Role Of Abhd11-as1 Lncrna In Human Cancersmentioning

confidence: 99%

Section: Molecular Mechanisms Of Abhd11-as1 Lncrna Dysregulation In H...mentioning

confidence: 99%

See 1 more Smart Citation

ABHD11-AS1: An Emerging Long Non-Coding RNA (lncRNA) with Clinical Significance in Human Malignancies

Golla

Sesham

Dallavalasa

et al. 2022

ncRNA

View full text Add to dashboard Cite

show abstract

“…Concerning lncRNAs, a study group analyzed the role of LncRNA ABHD11-AS1 in a series of PTCs. They detected ABHD11-AS1 high expression levels that led to increased activation EPS15L1/EGFR pathway (30).…”

Section: Egfr Alterations In Thyroid Carcinomamentioning

confidence: 99%

Anti-EGFR/BRAF-Tyrosine Kinase Inhibitors in Thyroid Carcinoma

Papanikolaou¹,

Kyrodimos²,

Mastronikolis³

et al. 2023

CDP

View full text Add to dashboard Cite

Alterations in significant genes located on chromosome 7 - including epidermal growth factor receptor (EGFR) and also v-Raf murine sarcoma viral oncogene homolog B (BRAF) as a mitogen-activated protein kinase (MAPK) - combined or not with numerical imbalances of the whole chromosome (aneuploidy-polysomy) are crucial genetic events involved in the development and progression of malignancies. Identification of EGFR/BRAF-dependent specific somatic mutations and other mechanisms of deregulation (i.e., amplification) is critical for applying targeted therapeutic approaches [tyrosine kinase inhibitors (TKIs] or monoclonal antibodies (mAbs). Thyroid carcinoma is a specific pathological entity characterized by a variety of histological sub-types. Follicular thyroid carcinoma (FTC), papillary thyroid carcinoma (PTC), medullary thyroid carcinoma (MTC), and anaplastic thyroid carcinoma (ATC) represent its main sub-types. In the current review, we explore the role of EGFR/BRAF alterations in thyroid carcinoma in conjunction with the corresponding anti-EGFR/BRAF TKI-based novel therapeutic strategies for patients with specific genetic signatures.

show abstract

“…LncRNA ABHD11-AS1, located at human chromosome 7 q11.23, has been proven to be related to many cancers, including cervical cancer, endometrial carcinoma, bladder cancer, and colorectal cancer [ 23 , 24 ]. It has been reported that ABHD11-AS1 promoted papillary thyroid carcinoma tumor progression by regulating the EPS15L1/EGFR pathway [ 25 ]. In addition, ABHD11-AS1 promoted cell proliferation and increased tumorigenicity in endometrial carcinoma by targeting cyclinD1 [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

LncRNA ABHD11-AS1 activates EGFR signaling to promote cervical cancer progression by preventing FUS-mediated degradation of ABHD11 mRNA

Yang,

Tian,

Zhao

et al. 2023

Cell Cycle

View full text Add to dashboard Cite

Cervical cancer is one of the most common gynecological cancers with high metastasis, poor prognosis and conventional chemotherapy. The long non-coding RNA (lncRNA) ABHD11 antisense RNA 1 (ABHD11-AS1) plays a vital role in tumorigenesis and is involved in cell proliferation, differentiation, and apoptosis. Especially for cervical cancer, the functions and mechanisms of ABHD11-AS1 are still undetermined. In this study, we explored the role and underlying mechanism of ABHD11-AS1 in cervical cancer. We found that ABHD11-AS1 is highly expressed in cervical cancer tissue. The roles of ABHD11-AS1 and EGFR have investigated the loss of function analysis and cell movability in SiHa and Hela cells. Knockdown of ABHD11-AS1 and EGFR significantly inhibited the proliferation, migration, and invasion and promoted apoptosis of SiHa and Hela cells by up-regulating p21 and Bax and down-regulating cyclin D1, Bcl2, MMP9, and Vimentin. ABHD11-AS1 knockdown could decrease the expression of EGFR. In addition, ABHD11-AS1 could regulate the EGFR signaling pathway, including p-EGFR, p-AKT, and p-ERK. Spearman’s correlation analysis and cell experiments demonstrated that ABHD11 was highly expressed in tumor tissue and partially offset the effect of shABHD11-AS1 on the proliferation, migration, and invasion of SiHa and Hela cells. Then, RNA pulldown was used to ascertain the mechanisms of ABHD11-AS1 and FUS. ABHD11-AS1 inhibited ABHD11 mRNA degradation by bounding to FUS. A subcutaneous xenograft of SiHa cells was established to investigate the effect of ABHD11-AS1 in tumor tissue. Knockdown of ABDH11-AS1 inhibited tumor growth and decreased the tumor volume. ABHD11-AS1 knockdown inhibited the expression of Ki67 and Vimentin and up-regulated the expression of Tunel. Our data indicated that ABHD11-AS1 promoted cervical cancer progression by activating EGFR signaling, preventing FUS-mediated degradation of ABHD11 mRNA. Our findings provide novel insights into the potential role of lncRNA in cervical cancer therapy.

show abstract

LncRNA ABHD11-AS1 promotes tumor progression in papillary thyroid carcinoma by regulating EPS15L1/EGFR signaling pathway

Cited by 5 publications

References 31 publications

ABHD11-AS1: An Emerging Long Non-Coding RNA (lncRNA) with Clinical Significance in Human Malignancies

ABHD11-AS1: An Emerging Long Non-Coding RNA (lncRNA) with Clinical Significance in Human Malignancies

Anti-EGFR/BRAF-Tyrosine Kinase Inhibitors in Thyroid Carcinoma

LncRNA ABHD11-AS1 activates EGFR signaling to promote cervical cancer progression by preventing FUS-mediated degradation of ABHD11 mRNA

Contact Info

Product

Resources

About